1835-12-7

Basic information

• Product Name: 4-(Benzyloxy)-3-methoxyphenacyl Bromide
• Synonyms: 4-(Benzyloxy)-3-methoxyphenacyl Bromide;2-BroMo-1-[3-Methoxy-4-(phenylMethoxy)phenyl]ethanone;4'-(Benzyloxy)-2-broMo-3'-Methoxy-acetophenone
• CAS NO: 1835-12-7
• Molecular Formula: C₁₆H₁₅BrO₃
• Molecular Weight: 335.1925
• Product Categories: Aromatics;Intermediates;Aromatics, Intermediates
• Mol File: 1835-12-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: 4-(Benzyloxy)-3-methoxyphenacyl Bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Benzyloxy)-3-methoxyphenacyl Bromide(1835-12-7)
• EPA Substance Registry System: 4-(Benzyloxy)-3-methoxyphenacyl Bromide(1835-12-7)

Safety Data

• Hazardous Substances Data: 1835-12-7(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Upstream product

• 100-44-7 benzyl chloride 
• 906668-05-1 2-(2,6-dimethoxyphenoxy)-1-(4-hydroxy-3-methoxyphenyl)ethan-1-one 
• 52041-27-7 1-(3'-methoxy-4'-(1-phenyl)methoxyphenyl)-2-(2'',6''-dimethoxyphenoxy)ethanal 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 100-39-0 benzyl bromide 
• 1835-11-6 4-benzyloxy-3-methoxyacetophenone 

Downstream Products

• 857560-88-4 1-(4-benzyloxy-3-methoxy-phenyl)-2-(2-methoxy-4-propyl-phenoxy)-ethanone 
• 857597-68-3 4-(4-benzyloxy-3-methoxy-phenacyloxy)-3-methoxy-benzaldehyde 
• 22317-29-9 1-(4-(benzyloxy)-3-methoxyphenyl)-2-(2-methoxyphenoxy)ethan-1-one 
• 144877-82-7 α-(4-hydroxymethyl-2-methoxyphenoxy)-4-benzyloxy-3-methoxyacetophenone 
• 73053-69-7 (+/-)-trans-1-(4-benzyloxy-3-methoxyphenacyl)-5-ethyl-2-oxo-4-piperidineacetic acid ethyl ester 
• 82260-54-6 (3R,4S)-(+)-1-(4-benzyloxy-3-methoxyphenacyl)-3-ethyl-4-piperidineacetic acid ethyl ester 
• 115075-64-4 (4R,5R)-1-(4-benzyloxy-3-methoxyphenacyl)-5-ethyl-2-oxo-4-piperidineacetic acid ethyl ester 
• 165054-55-7 1-(4-Benzyloxy-3-methoxyphenyl)-2-(5,5'-dipropyl-3,3'-dimethoxy-2'-hydroxy-1,1'-biphenyl-2-yloxy)ethanone 
• 52041-27-7 1-(3'-methoxy-4'-(1-phenyl)methoxyphenyl)-2-(2'',6''-dimethoxyphenoxy)ethanal 
• 26513-91-7 ω-<2-Methoxy-4-methyl-phenoxy>-4-acetoguajcon-benzylaether 
• 1879-23-8 1-<4-Benzyloxy-3-methoxy-phenyl>-2-acetoxy-aethanon 
• 26593-70-4 2-<2-Methoxy-4-methyl-phenoxy->-1-<4-hydroxy-3-methoxy-phenyl>-aethanol-(1) 
• 26514-00-1 2-<2-Methoxy-4-methyl-phenoxy->-1-acetylmercapto-1-<4-hydroxy-3-methoxy-phenyl>-aethan 
• 26513-95-1 β-Hydroxy-α-(2-methoxy-4-methyl-phenoxy-)-4-propio-guajacon-benzylether 

Relevant articles and documents

Thio-assisted reductive electrolytic cleavage of lignin β-O-4 models and authentic lignin

Avoiding the use of expensive catalysts and harsh conditions such as elevated temperatures and high pressures is a critical goal in lignin depolymerization and valorization. In this study, we present a thio-assisted electrocatalytic reductive approach using inexpensive reticulated vitreous carbon (RVC) as the working cathode to cleave the β-O-4-type linkages in keto aryl ethers. In the presence of a pre-electrolyzed disulfide (2,2′-dithiodiethanol) and a radical inhibitor (BHT) at room temperature at a current density of 2.5 mA cm-2, cathodic reduction of nonphenolic β-O-4 dimers afforded over 90% of the corresponding monomeric C-O cleavage products in only 1.5 h. Extended to DDQ-oxidized poplar lignin, this combination of electric current and disulfide, applied over 6 h, released 36 wt% of ethyl acetate soluble fragments and 26 wt% of aqueous soluble fragments, leaving only 38 wt% of insoluble residue. These findings represent a significant improvement over the current alone values (24 wt% ethyl acetate soluble; 22 wt% aqueous soluble; 54 wt% insoluble residue) and represent an important next step in our efforts to develop a mild electrochemical method for reductive lignin deconstruction.

TGFβ INHIBITOR AND PRODRUGS

A compound of formula (I) with improved TGFβ signaling pathway inhibitory activity, improved therapeutic efficacy and improved toxicity profile, as well as two prodrugs thereof are disclosed. Compositions comprising said TGFβ signaling pathway inhibitor a

Synthesis and evaluations of novel apocynin derivatives as anti-glioma agents

Apocynin (4-hydroxy-3-methoxyacetophenone) is a natural polyphenolic compound with multiple biological activities. In the present study, a series of apocynin derivatives were designed and synthesized. The in silico ADMET prediction, blood-brain barrier (B

A medicine for treating diseases of the nervous system of the new compound

The invention belongs to the technical fields of medicines, and relates to compounds having a structure represented as a formula I and pharmaceutically acceptable salts of the compounds, wherein the R1 and R2 are selected from a group consisting of hydrog

Iridium-catalysed primary alcohol oxidation and hydrogen shuttling for the depolymerisation of lignin

Lignin is a potentially abundant renewable resource for the production of aromatic chemicals, however its selective depolymerisation is challenging. Here, we report a new catalytic system for the depolymerisation of lignin to novel, non-phenolic monoaromatic products based on the selective β-O-4 primary alcohol dehydrogenation with a Cp?Ir-bipyridonate catalyst complex under basic conditions. We show that this system is capable of promoting the depolymerisation of model compounds and isolated lignins via a sequence of selective primary alcohol dehydrogenation, retro-aldol (Cα-Cβ) bond cleavage and in situ stabilisation of the aldehyde products by transfer (de)hydrogenation to alcohols and carboxylic acids. This method was found to give good to excellent yields of cleavage products with both etherified and free-phenolic lignin model compounds and could be applied to real lignin to generate a range of novel non-phenolic monomers including diols and di-acids. We additionally show, by using the same catalyst in a convergent, one-pot procedure, that these products can be selectively channelled towards a single di-acid product, giving much simpler product mixtures as a result.

A medicine for treating diseases of the nervous system of the new compound (by machine translation)

The invention belongs to the technical field of medicine, the compounds of the formula I structure and its pharmaceutically acceptable salt, Wherein R1, R2 is hydrogen, halogen; R3 is hydrogen, alkyl, benzyl, phenethyl. The invention also relates to the

Identification of Buctopamine and Mebuctopamine, a β2 Receptor Agonist and Its Metabolite, in Swine Hair and Feed Additives

4-[2-(t-Butylamino)-1-hydroxyethyl]phenol (buctopamine, 4), a new β2 receptor agonist (β2-agonist), was found to be an adulterant in feed additives for swine in Taiwan, where using β2-agonists in food-production animals is

Synthesis of a trimeric lignin model compound composed of α-O-4 and β-O-4 linkages under microwave irradiation

A trimeric lignin model compound composed of α-O-4 and β-O-4 linkages was prepared by the microwave-assisted synthesis, which consisted of three steps: (a) the synthesis of 3-methoxy-4-benzyloxyacetophenone (2) from acetovanillone (1), (b) the bromination

(THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS

The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

PHENYLIMIDAZOLE COMPOUNDS

[Object] To provide a pharmaceutical product (chemotherapeutic agent) effective in the prevention and treatment of hyperlipidemia, obesity, etc. [Solving Means] A phenylimidazole compound represented by the following General Formula (1): wherein, R1